

Forward Looking Statement

The statements made by Applied DNA Sciences, Inc. ("the Company", or "us") herein regarding the Company and its business may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe the Company's future plans, projections, strategies and expectations, including statements regarding future results of operations and financial position, business strategy, prospective products, timing and likelihood of success, and objectives of management for future operations, and are based on certain assumptions and involve a number of risks and uncertainties, many of which are beyond the control of the Company, including, but not limited to, the risks detailed in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2017, and other reports filed by the Company with the Securities and Exchange Commission. Forward-looking statements include all statements which are not historical facts, and can generally be identified by terms such as anticipates, believes, could, estimates, intends, may, plans, projects, should, will, would, or the negative of those terms and similar expressions.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and may be beyond the Company's control, you should not rely on these statements as predictions of future events. Actual results could differ materially from those projected due to our lack of significant revenues, limited financial resources, history of losses, lack of market acceptance of our products and services, shifting enforcement priorities of US federal laws relating to cannabis, market competition, changes in the local and national economies, and various other factors. All forward-looking statements contained herein speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements, whether to reflect new information, events or circumstances after the date hereof or otherwise.

Statement of Operations

	Three Month Period Ended				Nine Month Period Ended			
	June 30,		Variance		June 30,		Variance	
	2018	2017	\$	%	2018	2017	\$	%
Revenues								
Product revenues	\$ 393,758	\$ 1,493,449	(1,099,691)	-74%	\$ 1,230,232	\$ 2,887,054	(1,656,822)	-57%
Service revenues	622,597	303,933	318,664	105%	1,477,746	718,709	759,037	106%
Total revenues	1,016,355	1,797,382	(781,027)	-43%	2,707,978	3,605,763	(897,785)	-25%
Cost of revenues	252,562	232,348	20,214	9%	956,155	804,552	151,603	19%
Cost of revenues as a % of product revenues	64%	16%			78%	28%		
Operating expenses:								
Selling, general and administrative	2,882,158	3,402,817	(520,659)	-15%	7,471,917	10,534,105	(3,062,188)	-29%
Research and development	625,006	603,095	21,911	4%	2,034,886	1,757,616	277,270	16%
Depreciation and amortization	122,999	161,441	(38,442)	-24%	425,927	486,786	(60,859)	-13%
Total operating expenses	3,630,163	4,167,353	(537,190)	-13%	9,932,730	12,778,507	(2,845,777)	-22%
LOSS FROM OPERATIONS	(2,866,370)	(2,602,319)	(264,051)	10%	(8,180,907)	(9,977,296)	1,796,389	-18%
Interest income (expense)	-	228	(228)	-100%	-	2,763	(2,763)	-100%
Other income (expense)	(21,353)	(8,758)	(12,595)	144%	(36,738)	(26,556)	(10,182)	38%
NET LOSS	\$ (2,887,723)	\$ (2,610,849)	(276,874)	11%	\$ (8,217,645)	\$ (10,001,089)	1,783,444	-18%
Net loss per share-basic and diluted	\$ (0.10)	\$ (0.10)			\$ (0.28)	\$ (0.38)		
Weighted average shares outstanding- basic and diluted	30,112,057	26,374,023			29,290,555	26,049,866		

EBITDA

	Three Month Period Ended			Nine Month Period Ended		
	June 30,			June 30,		
	2018	2017	% Δ	2018	2017	% Δ
Net Loss	\$ (2,887,723)	\$ (2,610,849)		\$(8,217,645)	\$(10,001,089)	
Interest expense (income), net	-	(228)		-	(2,763)	
Depreciation and amortization	122,999	161,441		425,927	486,786	
Stock based compensation expense (income)	238,738	566,377		184,806	2,562,300	
Bad debt expense	3,434	346,921		20,551	368,168	
Total non-cash items	365,171	1,074,511		631,284	3,414,491	
Consolidated Adjusted EBITDA (loss)	\$ (2,522,552)	\$ (1,536,338)	64%	\$(7,586,361)	\$(6,586,598)	15%



Comparative Consolidated Balance Sheets

	<u>June 30, 2018</u> (unaudited)	<u>September 30, 2017</u>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 2,514,816	\$ 2,959,781
Accounts receivable, net	1,414,948	2,587,969
Inventories	295,278	326,468
Prepaid expenses and other current assets	602,800	366,954
Total current assets	4,827,842	6,241,172
Property and equipment, net	535,805	523,688
Other assets:		
Deposits	62,380	61,626
Intangible assets:		
Goodwill	285,386	285,386
Intangible assets, net	896,562	1,042,076
Total assets	\$ 6,607,975	\$ 8,153,948
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 818,642	\$ 944,133
Deferred revenue	2,298,152	351,735
Total current liabilities	3,116,794	1,295,868
Long term accrued liabilities	433,051	-
Total liabilities	3,549,845	1,295,868
Commitments and contingencies		
Stockholder's Equity		
Common stock	30,112	27,377
Additional paid in capital	247,918,818	243,503,858
Accumulated deficit	(244,890,800)	(236,673,155)
Total stockholder's equity	3,058,130	6,858,080
Total liabilities and stockholder's equity	\$ 6,607,975	\$ 8,153,948

Biotech Trifecta

Great Science ✓

Huge Markets ✓

Strong IP ✓




cGMP PCR Production of DNA

- Protected by four issued patents
- Large-scale DNA tagging applications
- Agriculture
- BioPharmaceutic applications:
 - Diagnostics - lab and point of care
 - Therapeutics - immunotherapy, gene therapy (recombinant expression), DNA/RNA vaccines (transient expression)



“The Wall”





applieddnasciences

Market Opportunity

DNA / RNA
Vaccines

Personalized
Biosimilars

Sepsis Antibody
Countermeasures

Linear DNA Produced by
Large-Scale PCR

CAR-T
Immuno-Oncology

Engineered Tissues
(stem cells)

Anti-infective / Bioterrorism
Countermeasures